comparision of the two methylprednisolone regimens in patient with COVID-19

Comparision the efficacy of 2 regimen of methylprednisolone in patient with acute respiratory distress syndrome due to CVOID-19

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130917014693N13

Enrollment

Registered

2021-11-06

Start date

2021-11-22

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

?Acute respiratory distress syndrome of covid-19 pneumonia. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: 1000 miligrams of methylprednisolone every 24 hours for 3 days then 1 mg/kg of methylprednisolone every 12 hours for total of 10 days. Intervention 2: Intervention

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age more than 18 years old Severe acute respiratory injury with coronavirus infection symptoms during 10 days ago who needed for hospital admission infection with COVID-19 wich confirmed with nasal RT_PCR test or CT-scan imaging Mild to moderate acute respiratory distress syndrome No more than 24 hours have passed since their admission to the study. The patient should not be under aggressive mechanical respiration when entering the study. Consent to participate in the study.

Exclusion criteria

Exclusion criteria: Dissatisfaction of the patient or the patient's legal companion Pregnancy and lactation Chronic hemodialysis Heart failure patients Severe vasoplegic shock Pulmonary edema due to other causes like heart failure , cirrhosis, chronic kidney failure Not administrating corticosteroid more than 24 hours after beginning ARDS Severe hypoxemia If the patient expires lower than 3 days after beginning of corticosteroids

Design outcomes

Primary

Measure	Time frame
Mortality ratio of patients with acute respiratory distress syndrome due to covid-19. Timepoint: first of admission and time of discharge. Method of measurement: Counting.	—

Secondary

Measure	Time frame
Determine the need for respiratory support and determine changes to this support. Timepoint: every 24 hours. Method of measurement: Ventilation modality.;Determine the exact length of hospital stay until discharge. Timepoint: every 24 hours. Method of measurement: Counting number of days.;Determine the number of patients who need to receive hemoperfusion. Timepoint: Every 24 hours. Method of measurement: Count the number of patients and the frequency of hemoperfusion.;Determine the number of patients who need to receive other immunosuppressants such as tocilizumab. Timepoint: every 24 hours. Method of measurement: Counting the number of patients and the number of doses of other drugs.	—

Measure

Time frame

Determine the need for respiratory support and determine changes to this support. Timepoint: every 24 hours. Method of measurement: Ventilation modality.;Determine the exact length of hospital stay until discharge. Timepoint: every 24 hours. Method of measurement: Counting number of days.;Determine the number of patients who need to receive hemoperfusion. Timepoint: Every 24 hours. Method of measurement: Count the number of patients and the frequency of hemoperfusion.;Determine the number of patients who need to receive other immunosuppressants such as tocilizumab. Timepoint: every 24 hours. Method of measurement: Counting the number of patients and the number of doses of other drugs.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Sahraei

Shahid Beheshti University of Medical Sciences

z.sahraei@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026